Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

Data from the study showed that treatment with 2mg/kg dose of del-brax achieved greater than 50% mean reductions in DUX4 regulated genes for 12 patients at the four-month timepoint. The early data also showed trends of improving muscle strength and function in patients treated with this dosage. Shares of RNA were up 32.6% on Wednesday as investors cheered the results. The results show the potential of del-brax to address the underlying cause of FHSD, which is the abnormal expression of the DUX4 gene. Curren ...